Exact Mass: 371.1558

Exact Mass Matches: 371.1558

Found 79 metabolites which its exact mass value is equals to given mass value 371.1558, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Trazodone

2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one

C19H22ClN5O (371.1513)


A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) CONFIDENCE standard compound; INTERNAL_ID 712; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7040; ORIGINAL_PRECURSOR_SCAN_NO 7038 CONFIDENCE standard compound; INTERNAL_ID 712; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6960; ORIGINAL_PRECURSOR_SCAN_NO 6956 CONFIDENCE standard compound; INTERNAL_ID 712; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7037; ORIGINAL_PRECURSOR_SCAN_NO 7034 CONFIDENCE standard compound; INTERNAL_ID 712; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6996; ORIGINAL_PRECURSOR_SCAN_NO 6993 D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants CONFIDENCE standard compound; INTERNAL_ID 2271 D049990 - Membrane Transport Modulators Trazodone (AF-1161 free base) is a serotonin receptor antagonist and reuptake inhibitor. Trazodone can be used for the research of major depressive disorder. Trazodone also has potential for sleep disorder research[1].

   

isradipine

Isradipine (Dynacirc)

C19H21N3O5 (371.1481)


C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Isradipine

3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

C19H21N3O5 (371.1481)


Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

2-Methoxy-4-(2-(methylamino)propyl)phenyl beta-D-glucopyranosiduronic acid

3,4,5-trihydroxy-6-{2-methoxy-4-[2-(methylamino)propyl]phenoxy}oxane-2-carboxylic acid

C17H25NO8 (371.158)


   

2-[6-(4-Chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine

N-[6-(4-chlorophenoxy)hexyl]-N-cyano-N-(pyridin-4-yl)guanidine

C19H22ClN5O (371.1513)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

Darodipine

3,5-Diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid

C19H21N3O5 (371.1481)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

N-(9H-Fluoren-9-ylacetyl)-L-phenylalanine

2-{[2-(9H-fluoren-9-yl)-1-hydroxyethylidene]amino}-3-phenylpropanoate

C24H21NO3 (371.1521)


   

N-Hydroxymexiletine glucuronide

6-({[1-(2,6-dimethylphenoxy)propan-2-yl]amino}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

C17H25NO8 (371.158)


   

CHEMBL3526290

CHEMBL3526290

C24H21NO3 (371.1521)


   

SCHEMBL20626347

SCHEMBL20626347

C18H21N5O4 (371.1593)


   
   
   
   
   

trazodone

trazodone

C19H22ClN5O (371.1513)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Trazodone (AF-1161 free base) is a serotonin receptor antagonist and reuptake inhibitor. Trazodone can be used for the research of major depressive disorder. Trazodone also has potential for sleep disorder research[1].

   
   
   
   
   
   
   
   
   
   

Diethylpropion (metabolite XI Glucuronide)

Diethylpropion (metabolite XI Glucuronide)

C17H25NO8 (371.158)


   
   
   
   
   

JWH 018 N-pentanoic acid metabolite

5-(3-(1-naphthoyl)-1H-indol-1-yl)-pentanoic acid

C24H21NO3 (371.1521)


   

Phenylephrine 3-O-glucuronide

Phenylephrine 3-O-glucuronide

C17H25NO8 (371.158)


   
   

N6-(2-Phenylethyl)adenosine

N6-(2-Phenylethyl)adenosine

C18H21N5O4 (371.1593)


N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine), an adenosine derivative, is a potent adenosine receptors (AR) agonist with Ki values of 11.8 nM, 30.1 nM, 0.63 nM for rat A1AR, human A1AR and hA3AR, respectively[1]. N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine), an adenosine derivative, is a potent adenosine receptors (AR) agonist with Ki values of 11.8 nM, 30.1 nM, 0.63 nM for rat A1AR, human A1AR and hA3AR, respectively[1].

   

(R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propanamide

(R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propanamide

C22H20F3NO (371.1497)


   
   

1-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylicacidhydrochloride;SKF89976AHCl

1-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylicacidhydrochloride;SKF89976AHCl

C22H26ClNO2 (371.1652)


SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.

   

1-Methyl-2-(tributylstannyl)-1H-pyrrole

1-Methyl-2-(tributylstannyl)-1H-pyrrole

C17H33NSn (371.1635)


   

(E)-1-(4,8-dimethoxynaphthalen-1-yl)-N-(1-prop-2-enylbenzimidazol-2-yl)methanimine

(E)-1-(4,8-dimethoxynaphthalen-1-yl)-N-(1-prop-2-enylbenzimidazol-2-yl)methanimine

C23H21N3O2 (371.1634)


   

Ethyl 3-amino-2-{[(2-cyano-4-biphenylyl)methyl]amino}benzoate

Ethyl 3-amino-2-{[(2-cyano-4-biphenylyl)methyl]amino}benzoate

C23H21N3O2 (371.1634)


   
   

Olanexidine

Olanexidine

C17H27Cl2N5 (371.1643)


C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D007004 - Hypoglycemic Agents > D001645 - Biguanides

   

1-Benzoyl-2,3-diphenylpyrrolidine-4-carboxylic acid

1-Benzoyl-2,3-diphenylpyrrolidine-4-carboxylic acid

C24H21NO3 (371.1521)


   

N-(1-(NAPHTHALEN-1-YL)ETHYL)-3-(3-(TRIFLUOROMETHYL)PHENYL)PROPANAMIDE

N-(1-(NAPHTHALEN-1-YL)ETHYL)-3-(3-(TRIFLUOROMETHYL)PHENYL)PROPANAMIDE

C22H20F3NO (371.1497)


   

Xanomeline oxalate

Xanomeline oxalate

C16H25N3O5S (371.1515)


Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease[1].

   
   

N,N-diMethyl-4-((E)-4-((E)-(4-nitrobenzylidene)aMino)styryl)aniline

N,N-diMethyl-4-((E)-4-((E)-(4-nitrobenzylidene)aMino)styryl)aniline

C23H21N3O2 (371.1634)


   

2-Oxazolidinone,3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]-4-(phenylmethyl)-,(4S)-

2-Oxazolidinone,3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]-4-(phenylmethyl)-,(4S)-

C21H22FNO4 (371.1533)


   

1-amino-4-[[4-[(dimethylamino)methyl]phenyl]amino]anthraquinone

1-amino-4-[[4-[(dimethylamino)methyl]phenyl]amino]anthraquinone

C23H21N3O2 (371.1634)


   

3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (4S)-

3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (4S)-

C19H21N3O5 (371.1481)


   

Darodipine

Darodipine

C19H21N3O5 (371.1481)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   
   

2-[1-[2-Oxo-2-[(4-thiophen-2-ylphenyl)methylamino]ethyl]cyclohexyl]acetic acid

2-[1-[2-Oxo-2-[(4-thiophen-2-ylphenyl)methylamino]ethyl]cyclohexyl]acetic acid

C21H25NO3S (371.1555)


   

1-[2-(2-Amino-3-cyano-1-pyrrolo[3,2-b]quinoxalinyl)ethyl]-3-phenylurea

1-[2-(2-Amino-3-cyano-1-pyrrolo[3,2-b]quinoxalinyl)ethyl]-3-phenylurea

C20H17N7O (371.1495)


   

2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-N-[(E)-pyridin-4-ylmethylideneamino]acetamide

2-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-N-[(E)-pyridin-4-ylmethylideneamino]acetamide

C19H22ClN5O (371.1513)


   

2-[3-(4-Methoxyphenyl)-1-benzo[f]quinolinyl]acetic acid ethyl ester

2-[3-(4-Methoxyphenyl)-1-benzo[f]quinolinyl]acetic acid ethyl ester

C24H21NO3 (371.1521)


   

2-(2,5-Difluorophenyl)-5-methyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]methyl]oxazole

2-(2,5-Difluorophenyl)-5-methyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]methyl]oxazole

C19H19F2N5O (371.1558)


   

4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylic acid O3-methyl ester O5-propan-2-yl ester

4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylic acid O3-methyl ester O5-propan-2-yl ester

C19H21N3O5 (371.1481)


   

1-(2-chlorophenyl)-N-[(1-cyclopentyl-5-tetrazolyl)methyl]-N-(2-furanylmethyl)methanamine

1-(2-chlorophenyl)-N-[(1-cyclopentyl-5-tetrazolyl)methyl]-N-(2-furanylmethyl)methanamine

C19H22ClN5O (371.1513)


   

(2R,3S,4R)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

(2R,3S,4R)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

C23H21N3O2 (371.1634)


   

(2R,3R,4S)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

(2R,3R,4S)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

C23H21N3O2 (371.1634)


   

(2S,3R,4S)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

(2S,3R,4S)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-[1-oxo-2-(2-pyridinyl)ethyl]-2-azetidinecarbonitrile

C23H21N3O2 (371.1634)


   

(2S,3R,4R)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-(2-pyridin-2-ylacetyl)azetidine-2-carbonitrile

(2S,3R,4R)-3-[4-(2-cyclopropylethynyl)phenyl]-4-(hydroxymethyl)-1-(2-pyridin-2-ylacetyl)azetidine-2-carbonitrile

C23H21N3O2 (371.1634)


   

2-[(2S,5R,6S)-5-(ethylsulfonylamino)-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridinylmethyl)acetamide

2-[(2S,5R,6S)-5-(ethylsulfonylamino)-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridinylmethyl)acetamide

C16H25N3O5S (371.1515)


   

(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C20H22FN3O3 (371.1645)


   

2-[(2S,5S,6R)-5-(ethylsulfonylamino)-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridinylmethyl)acetamide

2-[(2S,5S,6R)-5-(ethylsulfonylamino)-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridinylmethyl)acetamide

C16H25N3O5S (371.1515)


   

(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C20H22FN3O3 (371.1645)


   
   
   
   
   
   
   
   
   
   
   
   
   

GMX1778

2-[6-(4-Chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine

C19H22ClN5O (371.1513)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor